Therapeutic Areas - Primary Hyperoxaluria Type 1 (PH1)
The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval. Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Primary Hyperoxaluria Type 1 (PH1)
Image
Primary Hyperoxaluria Type 1 (PH1) is a rare, metabolic disorder caused by alanine-glyoxylate aminotransferase (AGXT) gene mutations that result in a deficiency of liver-specific peroxisomal alanine-glyoxylate aminotransferase (AGT) and consequent overproduction of oxalate by the liver. Continuous oxalate overproduction may lead to progressive damage in the kidneys and other organs.1,2
Resources
References:
- Fargue S, Acquaviva Bourdain C. Clin Kidney J. 2022;15(Suppl 1):i4-i8.
- Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264-1271.
